This study is looking at how two medications, Finerenone and Empagliflozin, might help African American veterans with diabetic kidney disease. Researchers want to understand if these drugs can reduce kidney damage by looking at specific markers (podocyte specific proteins) in urine. You might be able to join if you are an African American veteran between 20 and 90 years old, have type 2 diabetes, and certain levels of kidney function (eGFR between 25-89 mL/min/1.73 m2) and protein in your urine (albuminuria of 30 mg/g or higher). The study aims to enroll 30 participants. The main goal is to see changes in these kidney damage markers after 16 weeks of treatment.

Study design

This is an interventional study with a planned enrollment of 30 participants. The phase of the study is not specified.

What's involved

Participants will take Finerenone 10 mg orally daily or Empagliflozin 10 mg orally daily for 4 months. Urine exosome assays will be measured at 16 weeks.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint is measured at 16 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.